These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 11523539)

  • 41. EBNA-1 sequence variations reflect active EBV replication and disease status or quiescent latency in lymphocytes.
    Wang JT; Sheeng TS; Su IJ; Chen JY; Chen MR
    J Med Virol; 2003 Mar; 69(3):417-25. PubMed ID: 12526054
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Epstein-Barr virus: biology and disease.
    Cruchley AT; Williams DM; Niedobitek G; Young LS
    Oral Dis; 1997 May; 3 Suppl 1():S156-63. PubMed ID: 9456681
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The Translesion Polymerase Pol η Is Required for Efficient Epstein-Barr Virus Infectivity and Is Regulated by the Viral Deubiquitinating Enzyme BPLF1.
    Dyson OF; Pagano JS; Whitehurst CB
    J Virol; 2017 Oct; 91(19):. PubMed ID: 28724765
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A single nucleotide polymorphism in the Epstein-Barr virus genome is strongly associated with a high risk of nasopharyngeal carcinoma.
    Feng FT; Cui Q; Liu WS; Guo YM; Feng QS; Chen LZ; Xu M; Luo B; Li DJ; Hu LF; Middeldorp JM; Ramayanti O; Tao Q; Cao SM; Jia WH; Bei JX; Zeng YX
    Chin J Cancer; 2015 Dec; 34(12):563-72. PubMed ID: 26675171
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Epstein-Barr virus infection and human malignancies.
    Niedobitek G; Meru N; Delecluse HJ
    Int J Exp Pathol; 2001 Jun; 82(3):149-70. PubMed ID: 11488990
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Resveratrol inhibits proliferation and survival of Epstein Barr virus-infected Burkitt's lymphoma cells depending on viral latency program.
    De Leo A; Arena G; Stecca C; Raciti M; Mattia E
    Mol Cancer Res; 2011 Oct; 9(10):1346-55. PubMed ID: 21856773
    [TBL] [Abstract][Full Text] [Related]  

  • 47. EVIDENCE OF EPSTEIN-BARR VIRUS ASSOCIATION WITH HEAD AND NECK CANCERS: A REVIEW.
    Prabhu SR; Wilson DF
    J Can Dent Assoc; 2016 Jan; 82():g2. PubMed ID: 27548665
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Noninvasive diagnosis of nasopharyngeal carcinoma: nasopharyngeal brushings reveal high Epstein-Barr virus DNA load and carcinoma-specific viral BARF1 mRNA.
    Stevens SJ; Verkuijlen SA; Hariwiyanto B; Harijadi ; Paramita DK; Fachiroh J; Adham M; Tan IB; Haryana SM; Middeldorp JM
    Int J Cancer; 2006 Aug; 119(3):608-14. PubMed ID: 16572427
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Epstein-Barr virus latent membrane protein-1 activates CD25 expression in lymphoma cells involving the NFkappaB pathway.
    Vockerodt M; Tesch H; Kube D
    Genes Immun; 2001 Dec; 2(8):433-41. PubMed ID: 11781710
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Epstein-Barr virus and Hodgkin's disease: transcriptional analysis of virus latency in the malignant cells.
    Deacon EM; Pallesen G; Niedobitek G; Crocker J; Brooks L; Rickinson AB; Young LS
    J Exp Med; 1993 Feb; 177(2):339-49. PubMed ID: 8381153
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Nasopharyngeal carcinoma in sub-Saharan Africa: a tribute to Mr. Peter Clifford].
    Griffin BE
    Ai Zheng; 2009 Aug; 28(8):785-90. PubMed ID: 19664323
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Epstein-Barr virus and the pathogenesis of Burkitt's lymphoma: more questions than answers.
    Bornkamm GW
    Int J Cancer; 2009 Apr; 124(8):1745-55. PubMed ID: 19165855
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Prognostic role of tumour-associated macrophages and regulatory T cells in EBV-positive and EBV-negative nasopharyngeal carcinoma.
    Ooft ML; van Ipenburg JA; Sanders ME; Kranendonk M; Hofland I; de Bree R; Koljenović S; Willems SM
    J Clin Pathol; 2018 Mar; 71(3):267-274. PubMed ID: 28877959
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Epstein-Barr virus (EBV) associated lesions of the head and neck.
    Boulter A; Johnson NW; Birnbaum W; Teo CG
    Oral Dis; 1996 Jun; 2(2):117-24. PubMed ID: 8957923
    [No Abstract]   [Full Text] [Related]  

  • 55. Clinical utility of circulating Epstein-Barr virus DNA analysis for the management of nasopharyngeal carcinoma.
    Fung SY; Lam JW; Chan KC
    Chin Clin Oncol; 2016 Apr; 5(2):18. PubMed ID: 27121878
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Epstein-Barr virus, the TCL-1 oncogene and Burkitt's lymphoma.
    Bell A; Rickinson AB
    Trends Microbiol; 2003 Nov; 11(11):495-7. PubMed ID: 14607063
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Characterization of Epstein-Barr virus-encoded small RNA gene variations in virus associated lymphomas in Northern China.
    Zhao Z; Sun L; Liu S; Shu J; Luo B
    Arch Virol; 2017 Jun; 162(6):1609-1616. PubMed ID: 28220325
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Interferon-γ-inducible protein 16 (IFI16) is required for the maintenance of Epstein-Barr virus latency.
    Pisano G; Roy A; Ahmed Ansari M; Kumar B; Chikoti L; Chandran B
    Virol J; 2017 Nov; 14(1):221. PubMed ID: 29132393
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Epstein-Barr virus and Burkitt's lymphoma worldwide: the causal relationship revisited.
    de-Thé G
    IARC Sci Publ; 1985; (60):165-76. PubMed ID: 2998987
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The role of Epstein Barr virus (EBV) in Burkitt's lymphomas.
    zur Hausen H
    Jpn J Cancer Res; 1998 Mar; 89(3):inside cover. PubMed ID: 9600115
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.